Brought to you by 
Invitrogen buys Applied Biosystems for $6.3bn
20 Sep 2012
Executive Summary
Invitrogen is buying Applera's Applied Biosystems Group for $6.3bn. Holders of Applera-Applied Biosystems common stock will receive $38 (a 12% premium and contingent upon Invitrogen's share price when the transaction closes) in Invitrogen stock and cash for each share they own. (Invitrogen estimates a split between cash and stock of 45% and 55%, respectively).
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Invitrogen buys Applied Biosystems for $6.3bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice